USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT
The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
1 - 153 . (canceled)
154 . A method of validating a target for therapeutic intervention in a disease, the method comprising:
(a) determining by ribosome profiling using natural, unmodified ribosomes a first translational profile for a plurality of genes from a disease sample that has been contacted with an agent that modulates a target;
(b) determining by ribosomal profiling using natural, unmodified ribosomes a second translational profile for a plurality of genes from a control disease sample that has not been contacted with the agent; and
(c) validating the target for therapeutic intervention in the disease to provide a biological benefit when one or more genes are differentially translated by at least two-fold in the first translational profile as compared to the second translational profile.
155 . The method of claim 154 , wherein the one or more differentially translated genes have a 5′ terminal oligopyrimidine tract (5′ TOP), a pyrimidine-rich translational element (PRTE), or both a 5′ TOP sequence and a PRTE sequence.
156 . The method of claim 154 , wherein the one or more differentially translated genes are selected from the group consisting of SEQ ID NOs:1-144.
157 . The method of claim 154 , wherein the one or more differentially translated genes comprises a plurality of genes.
158 . The method of claim 157 , wherein the plurality of genes comprise one or more gene signatures or are from one or more biological pathways.
159 . The method of claim 158 , wherein the biological pathway is selected from a protein synthesis pathway, a cell invasion/metastasis pathway, a cell division pathway, an apoptosis pathway, a signal transduction pathway, a cellular transport pathway, a posttranslational protein modification pathway, a DNA repair pathway, and a DNA methylation pathway.
160 . The method of claim 154 , wherein the disease is selected from the group consisting of a cancer, an inflammatory disease, an autoimmune disease, a fibrotic disorder, a neurodegenerative disease, a neurodevelopmental disease, a metabolic disease, and a viral infection.
161 . The method of claim 160 , wherein the disease is a cancer selected from the group consisting of prostate cancer, breast cancer, bladder cancer, lung cancer, renal cell carcinoma, endometrial cancer, melanoma, ovarian cancer, thyroid cancer, and brain cancer.
162 . The method of claim 161 , wherein the cancer is prostate cancer.
163 . The method of claim 154 , wherein each translational profile comprises a genome-wide translational profile.
164 . The method of claim 163 , wherein less than about 20% of the genes in the genome are differentially translated in the first translational profile as compared to the second translational profile.
165 . The method of claim 163 , wherein less than about 5% or less than about 1% of the genes in the genome are differentially translated by at least two-fold in the first translational profile as compared to the second translational profile.
166 . A method for treating a disease comprising administering to a subject having the disease an agent that modulates a target, wherein the target was validated according to the method of claim 154 , thereby treating the subject.
167 . The method for claim 166 , wherein the disease is selected from the group consisting of a cancer, an inflammatory disease, an autoimmune disease, a neurodegenerative disease, a neurodevelopmental disease, a metabolic disease, and a viral infection.
168 . The method of claim 167 , wherein the disease is a cancer selected from the group consisting of prostate cancer, breast cancer, bladder cancer, lung cancer, renal cell carcinoma, endometrial cancer, melanoma, ovarian cancer, thyroid cancer, and brain cancer.
169 . The method of claim 168 , wherein the cancer is prostate cancer.
170 . The method of claim 166 , wherein the agent that modulates the target is selected from the group consisting of a peptide, a protein, an oligopeptide, a circular peptide, a peptidomimetic, an antibody, a polysaccharide, a lipid, a fatty acid, an inhibitory RNA, a polynucleotide, an oligonucleotide, an aptamer, a small organic molecule, and a drug compound.
171 . The method of claim 170 , wherein the agent is a small organic molecule.
172 . The method of claim 170 , wherein the agent is a peptide or a protein.
173 . The method of claim 170 , wherein the agent is an inhibitory RNA.